HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China TCM (570.HK) Update - The Disappointing 24H1 Results Will Not Affect the Privatization Process

China TCM (570.HK) Privatization Update - The Long Stop Date to Extend or Not?

China Healthcare Weekly (Oct.20)-A Big Lesson from China TCM's Deal Break, “Must Option” of Biotech

Event-Driven

China Traditional Chinese Medicine / Event-Driven

China Traditional Chinese Medicine (570 HK)

<ul>
<li>The real reason for CNPGC’s decision to abandon its promise may be "extraordinary". The "national security issue" seems to be a more reasonable explanation for the failure of this privatization.</li>
<li>A sustainable rebound in share prices will have to depend on obvious improvement in fundamentals and attractive dividends.We changed our valuation forecast. The investment logic of China TCM has changed.</li>
<li>China TCM may not deliver excess returns in the short term. If investors can't wait that long, offload directly and moving on to other opportunities is an option to consider.</li>
</ul>


The real reason for CNPGC’s decision to abandon its promise may be "extraordinary". The "national security issue" seems to be a more reasonable explanation for the failure of this privatization.
A sustainable rebound in share prices will have to depend on obvious improvement in fundamentals and attractive dividends.We changed our valuation forecast. The investment logic of China TCM has changed.
China TCM may not deliver excess returns in the short term. If investors can't wait that long, offload directly and moving on to other opportunities is an option to consider.


China TCM (570.HK) Update - The Real Reason For the Deal Break and the Valuation Outlook